Our in vivo study further confirmed the anti-tumor effect of arctigenin in obese conditions by showing a 45% inhibition of prostate tumor growth, along with significantly reduced tumor expression of the proliferation marker Ki67. The gene discussed is MKI67; the disease is prostate neoplasm.